Table III.
Relative Hazard Ratios for inclusion in the current study and gene alteration
| Relative Hazard Ratio | 95% Confidence Interval | Median follow-up* | Maximum follow-up* | |
|---|---|---|---|---|
|
| ||||
| Evaluated Status | ||||
| Not Evaluated | 1.0000 | 4.93 | 7.86 | |
| Evaluated | 1.2480 | 0.8779 to 1.7742 | 5.78 | 7.67 |
| CDKN2A Status | ||||
| Normal | 1.0000 | 5.62 | 7.67 | |
| Deleted | 0.9397 | 0.3337 to 2.6459 | 5.95 | 6.79 |
| TP53 Status | ||||
| Normal | 1.0000 | 5.50 | 7.60 | |
| Mutated | 1.8288 | 0.6450 to 5.1856 | 5.71 | 5.83 |
| CDKN2A&TP53 Status | ||||
| Both normal | 1.0000 | 5.44 | 7.60 | |
| Either/Both altered | 1.2638 | 0.5499 to 2.9046 | 5.82 | 6.71 |
*
Among patients without an event. Relative hazard ratio with 95% confidence intervals and follow-up durations for (1) AEWS0031 patients evaluated and not evaluated in the current study (AEWS08B1), and (2) patients with and without CDKN2A and/or TP53 alterations.